Orasis Pharmaceuticals
Reshaping Vision Possibilities
- Headquarters
- Tel Aviv
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- orasis-pharma.com
- Total Funding
- $121.0M
- Last Round
- $78.0M Growth EquityOct 2024
About
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on near vision correction. They developed Qlosi (pilocarpine hydrochloride 0.4%), a preservative-free prescription eye drop FDA-approved in 2023 for the treatment of presbyopia in adults. The company targets the nearly 128 million Americans living with age-related blurry near vision as an alternative to reading glasses or surgery.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account